Table 2.
Current and potential future therapeutics for LGL leukemia
RTK indicates receptor tyrosine kinase; sFas, soluble Fas; and MMP, matrix metalloproteinase.
Current and potential future therapeutics for LGL leukemia
RTK indicates receptor tyrosine kinase; sFas, soluble Fas; and MMP, matrix metalloproteinase.
